Tags : Initiates


Evotec and Exscientia Initiate Human Clinical Trials of their Novel

Shots: The companies initiate the clinical trial of A2a receptor antagonist, co-developed by Exscientia and Evotec utilizing Exscientia’s AI-design platform, Centaur Chemist Exscientia will lead the clinical development phase of the molecule and Evotec retains co-ownership rights throughout clinical development The A2a receptor is currently in development for adult patients with advanced solid tumors and […]Read More

Clinical Trials

Tetra Bio-Pharma Initiates Additional Studies of ARDS-003 in Neuroinflammation and

Shots: Tetra and Targeted Pharmaceuticals collaborated with George Mason University NCBID to examine the potential benefits of ARDS-003 in neuroinflammation and other antiviral applications The collaboration with Targeted provides expertise into the areas of drug development to expand the potential Return on Investment of ARDS-003 The agreement will advance the antiviral CNS program, which is […]Read More


Celltrion Initiates P-III Study of CT-P42 (biosimilar, aflibercept)

Shots: Celltrion has launched a global P-III clinical trial of CT-P42 which is an investigational biosimilar candidate referencing Regeneron’s Eylea (aflibercept) The study will enroll 300 patients with DME and aims to compare CT-P42’s efficacy, safety, pharmacokinetics, and immunogenicity against Eylea Celltrion adds CT-P42 to its pipeline of other investigational biosimilars, including CT-P17 (referencing Humira), […]Read More